China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2019 - 2025)

China SXT Pharmaceuticals' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $909904.0 for Q1 2025.

• In Q1 2025, Accumulated Expenses fell 6.04% year-over-year to $909904.0; the TTM figure through Mar 2025 stood at $909904.0 (down 6.04% YoY), while the FY2025 annual figure was $909904.0, down 6.04% from the prior year.
• Accumulated Expenses was $909904.0 for Q1 2025 at China SXT Pharmaceuticals, down from $968416.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q1 2023 to a low of $909904.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $1.7 million across 3 years, with a median of $968416.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 69.18% in 2024, then retreated 6.04% in 2025.
• A 3-year view of Accumulated Expenses shows it stood at $3.1 million in 2023, then plunged by 69.18% to $968416.0 in 2024, then declined by 6.04% to $909904.0 in 2025.
• The last three Accumulated Expenses figures came in at $909904.0 (Q1 2025), $968416.0 (Q1 2024), and $3.1 million (Q1 2023), per Business Quant data.